povorcitinib
Sponsor Incyte CORP · listed as INCY
povorcitinib is a drug asset sponsored by Incyte CORP, listed as INCY. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Dec 26, 2026 (day precision, medium confidence), tied to trial NCT06212999. That trial is in Phase 3 and currently active not recruiting, studying Hidradenitis Suppurativa (HS). It appears across 4 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for povorcitinib
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-26 | READOUT | medium | NCT06212999 |
| 2028-02-28 | READOUT | medium | NCT06855498 |
Trials for povorcitinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06113445 | Phase 3 | Active, not recruiting | 2026-02-24 | Experimental | Incyte Corporation | NonSegmental Vitiligo |
| NCT06113471 | Phase 3 | Active, not recruiting | 2026-03-17 | Experimental | Incyte Corporation | NonSegmental Vitiligo |
| NCT06212999 catalyst | Phase 3 | Active, not recruiting | 2026-12-26 | Experimental | Incyte Corporation | Hidradenitis Suppurativa (HS) |
| NCT06855498 catalyst | Phase 3 | Recruiting | 2028-02-28 | Experimental | Incyte Corporation | Hidradenitis Suppurativa (HS) |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More INCY catalysts